Launching novel oncology therapies in Asia: Identifying and communicating value
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success.
China: How to strategise and win in the world's fastest changing healthcare market
In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.
With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.
Real world evidence research breakfast seminar
We were delighted to attend and present a paper at the Tech Observer event in Singapore earlier this month
APAC Director Pei Li Teh, and Research Manager, Colin Tan, attended the event. Pei Li presented the paper ‘Inhale, exhale: How using real world data helped asthma patients breathe easier across Asia’. In her paper she demonstrated how published real world data research provided pharma companies with an in-depth understanding of asthma patients’ across Asia. The data provided the healthcare community with a tool to supply tailored communications supporting different patient types, instead of a ‘one size fits all’ approach.
Research Partnership welcomes Jeanne Penn
We are delighted to announce that Jeanne Penn has joined the Singapore office as a Senior Research Executive.
Jeanne previously worked at Cello Health Insight in New York City on the qualitative team, where she was involved in all parts of the research process, from writing proposals to delivering reports. She’s worked in various therapy areas, and has a particular interest in rare diseases and mental health. In a prior role, she co-led the first Diversity & Inclusion initiative and was awarded the Young Professionals Grant to attend the Qualitative Research Consultants Association (QRCA) conference. Jeanne graduated from Hamilton College, and interned at Hall & Partners where she was first introduced to healthcare market research.
How integrated insights supported a biologic launch strategy across multiple indications
Our client is launching a new biologic in immunology across several indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and reimbursement as well the pricing opportunity. They wanted to use the insights to develop the optimal launch strategy across 12 markets and across indications, and also support the local market access teams by conducting a mock negotiation with payers.